Japan’s 2-1 home defeat by UAE in September was marred by controversial refereeing decisions as the Samurai Blue appeared to have been denied an equaliser after the ball looked to have crossed the line. “The UAE defeat was a slap in the face for us. It still frustrates me and we can’t wait to put one over on them in March,” Halilhodzic was quoted as saying by Kyodo news on Thursday. Japan, who are currently tied on 10 points with Group B leaders Saudi Arabia after five games, travel to UAE on March 23 before hosting Thailand five days later. Japan are then away to Iraq on June 13, at home to Australia on Aug. 31 before wrapping up qualification away to Saudi Arabia on Sept. 5. “We have three away games in the Middle East and there has been a recent improvement among teams in the region,” Halilhodzic added. “I expect us to be put under a great deal of pressure.
For the original version including any supplementary images or video, visit http://sports.yahoo.com/news/soccer-halilhodzic-eager-japan-exact-revenge-over-uae-104407168–sow.html
These findings support further investigation of CR2 in specific GI indications where patients experience abdominal pain but are not necessarily constipated, such as IBS-Mixed, IBS with diarrhea, ulcerative colitis and diverticulitis. The companies plan to engage with the U.S. Food and Drug Administration (FDA) to discuss next steps for advancing CR2 into a Phase IIb dose-ranging clinical trial in patients with non-constipation subtypes of IBS. There is increasing research into the mechanisms underlying pain and other abdominal symptoms in GI disorders, including IBS, as well as research highlighting the hypersensitivity of pain-sensing nerves in the lower GI tract in many patients suffering from these conditions, said Brennan Spiegel, director of Health Services Research at Cedars-Sinai Health System. We currently have a limited number of treatment options for these patients, and a medicine that could address abdominal pain without impacting bowel function could represent a real advancement in care. Linaclotide is currently FDA-approved and available in an immediate release (IR) formulation, LINZESS, for the treatment of adults with IBS-C or chronic idiopathic constipation (CIC). http://url.de1.cc/medicalinterview52828Linaclotide is thought to work in two ways, based on non-clinical studies: by decreasing the activity of pain-sensing nerves and by increasing fluid secretion into the intestine. Linaclotide CR2 is designed to provide targeted delivery of linaclotide to the colon, where the majority of the abdominal pain associated with IBS-C is believed to originate. This clinical trial was designed to evaluate whether CR2 could further decrease the activity of key pain-sensing nerves in the colon with a minimal effect on fluid secretion. Ironwood and Allergan also announced topline results from the same Phase IIb trial with a second formulation, linaclotide colonic release-1 (CR1), in a separate press release issued today. The double-blind, placebo-controlled, dose-ranging Phase IIb trial randomized 532 adult patients with IBS-C into one of eight possible treatment arms.my blog
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/ironwood-allergan-report-topline-phase-120000899.html
You may also be interested to read
- website link
- medical residency interview questions